Takedatsu H - Search Results

1

Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles.

Minami T, Matsueda S, Takedatsu H, Tanaka M, Noguchi M, Uemura H, Itoh K, Harada M. Minami T, et al. Among authors: takedatsu h. Cancer Immunol Immunother. 2007 May;56(5):689-98. doi: 10.1007/s00262-006-0216-9. Epub 2006 Aug 26. Cancer Immunol Immunother. 2007. PMID: 16937115 Free PMC article.

2

Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.

Matsueda S, Takedatsu H, Yao A, Tanaka M, Noguchi M, Itoh K, Harada M. Matsueda S, et al. Among authors: takedatsu h. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6933-43. doi: 10.1158/1078-0432.CCR-05-0682. Clin Cancer Res. 2005. PMID: 16203785

3

Identification of human papillomavirus 16-E6 protein-derived peptides with the potential to generate cytotoxic T-lymphocytes toward human leukocyte antigen-A24+ cervical cancer.

Hara M, Matsueda S, Tamura M, Takedatsu H, Tanaka M, Kawano K, Mochizuki K, Kamura T, Itoh K, Harada M. Hara M, et al. Among authors: takedatsu h. Int J Oncol. 2005 Nov;27(5):1371-9. Int J Oncol. 2005. PMID: 16211234

4

Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma.

Wang Y, Harada M, Yano H, Ogasawara S, Takedatsu H, Arima Y, Matsueda S, Yamada A, Itoh K. Wang Y, et al. Among authors: takedatsu h. J Immunother. 2005 Nov-Dec;28(6):535-41. doi: 10.1097/01.cji.0000175490.26937.22. J Immunother. 2005. PMID: 16224270

5

New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles.

Matsueda S, Takedatsu H, Sasada T, Azuma K, Ishihara Y, Komohara Y, Noguchi M, Shichijo S, Itoh K, Harada M. Matsueda S, et al. Among authors: takedatsu h. J Immunother. 2007 Apr;30(3):274-81. doi: 10.1097/01.cji.0000211340.88835.e7. J Immunother. 2007. PMID: 17414318

6

Identification of two novel tumor-associated antigens recognized by HLA-B46-restricted cytotoxic T lymphocytes.

Shichijo S, Azuma K, Komatsu N, Kawamoto N, Takedatsu H, Shomura H, Sawamizu H, Maeda Y, Ito M, Itoh K. Shichijo S, et al. Among authors: takedatsu h. Int J Mol Med. 2003 Dec;12(6):895-902. Int J Mol Med. 2003. PMID: 14612963

7

Detection of a set of peptide vaccine candidates for use in HLA-A31+ epithelial cancer patients.

Takedatsu H, Shichijo S, Azuma K, Takedatsu H, Sata M, Itoh K. Takedatsu H, et al. Int J Oncol. 2004 Feb;24(2):337-47. Int J Oncol. 2004. PMID: 14719110

8

Identification of peptide vaccine candidates sharing among HLA-A3+, -A11+, -A31+, and -A33+ cancer patients.

Takedatsu H, Shichijo S, Katagiri K, Sawamizu H, Sata M, Itoh K. Takedatsu H, et al. Clin Cancer Res. 2004 Feb 1;10(3):1112-20. doi: 10.1158/1078-0432.ccr-0797-3. Clin Cancer Res. 2004. PMID: 14871991

9

Expression of epithelial cancer-related antigens in hematologic malignancies applicable for peptide-based immunotherapy.

Takedatsu H, Okamura T, Yoshimoto K, Harada M, Koga M, Shichijo S, Sata M, Itoh K. Takedatsu H, et al. J Immunother. 2004 Jul-Aug;27(4):289-97. doi: 10.1097/00002371-200407000-00005. J Immunother. 2004. PMID: 15235390

10

Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients.

Azuma K, Sasada T, Takedatsu H, Shomura H, Koga M, Maeda Y, Yao A, Hirai T, Takabayashi A, Shichijo S, Itoh K. Azuma K, et al. Among authors: takedatsu h. Clin Cancer Res. 2004 Oct 1;10(19):6695-702. doi: 10.1158/1078-0432.CCR-04-0818. Clin Cancer Res. 2004. PMID: 15475460

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

92 results

Search Page

Filters